EuroPCR 2022 | ASTRO TAVR: Should we treat post TAVR Strokes with Neurointervention?

The presence of stroke after TAVR has dropped and is currently at 2%; however, it is 5 times more deadly, has negatively affected quality of life and has increased healthcare costs. 

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

The ASTRO TAVI registry included 14 centers and 16615 TAVR procedures between 2006 y 2021. In this period, there were 484 neurological events within 30 days after procedure (2.9%). 387 of these events were ischemic strokes (2.3%) and 93 were excluded for lack of data, leaving 276 patients for analysis. Patients were either treated conservatively (CT) or received a neuro-intervention (NI) with thrombolysis or mechanical thrombectomy.

Primary end point was all cause mortality at 1 year and neurological disability at 90 days was assessed with the modified Rankin score.

Stroke was mild (NIHSS 0-5) in 149 patients (146 CT and 3 NI), moderate (NIHSS 6-15) in 71 (CT 56 and NI 15) and severe (NIHSS 16-42) in 74 (53 CT and 21 NI).

Most strokes presented within 48 hours, morality was higher in patients with severe stroke vs. moderate or mild, both at 30 days and 12 months. (57.6% vs. 18.4% vs.9% p<0.0001 and 77.5% vs. 36% vs. 29% p<0.0001).

Read also: EuroPCR 2022 | Changes in Cardiac Damage after Surgical Aortic Valve Replacement.

Where comparing patient treatments, there were no differences between patients with moderate and severe stoke. Neither were there differences when looking at aortic valve area, mean gradient and left ventricular function, which was conserved. Mean age was 81, 31% were diabetic, 71% hypertensive, 17% had COPD, 1,4 mg/L creatinine. 

Cerebroprotection was used in 6%, 80% were treated via femoral and 68% of valves were self-expanding. 

Mortality STS Score was 5.8%.

Read also: Transfemoral vs Transradial Approach in the Percutaneous Treatment of CTO.

General anesthesia was more frequent in patients receiving CT (43.5% vs 15.4% p=0.001).

At 12 months, even though there were no differences in mortality, there was lower neurological disability in patients undergoing neuro intervention at 90 days. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...